Menu
Search
|

Menu

Close
X

Flex Pharma Inc FLKS.OQ (NASDAQ Stock Exchange Global Market)

4.17 USD
+0.00 (+0.00%)
As of 2:29 AM IST
chart
Previous Close 4.17
Open 4.20
Volume 9
3m Avg Volume 13,040
Today’s High 4.20
Today’s Low 4.20
52 Week High 5.83
52 Week Low 2.68
Shares Outstanding (mil) 17.97
Market Capitalization (mil) 60.74
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
1
FY15
0
EPS (USD)
FY17
-1.004
FY16
-2.436
FY15
-2.102
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
41.15
5.77
Price to Book (MRQ)
vs sector
1.31
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-59.64
14.43
Return on Equity (TTM)
vs sector
-59.69
16.13

EXECUTIVE LEADERSHIP

Christoph Westphal
Chairman of the Board, Since 2017
Salary: $337,500.00
Bonus: --
William McVicar
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
John McCabe
Chief Financial Officer, Treasurer, Since 2016
Salary: $169,871.00
Bonus: --
Kathie Lindemann
Chief Operating Officer, Since 2015
Salary: --
Bonus: --
Jennifer Cermak
Vice President - Research & Development, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

800 Boylston St Fl 24
BOSTON   MA   02199-8119

Phone: +1617.8741821

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

SPONSORED STORIES